Who’s Eligible for Mounjaro? NHS & Private Prescription Criteria

The arrival of Mounjaro® (tirzepatide) has generated excitement for people struggling with obesity and related health conditions. However, this powerful weight‑loss medicine is not suitable for everyone and is available on the NHS only to those who meet strict criteria. Private clinics like Medcare Healthclinic & Pharmacy can prescribe the drug more flexibly, but still adhere to safety guidelines and clinical best practice. This article explains who can take Mounjaro, how eligibility differs between NHS and private services, and what to expect during the assessment process.

Understanding Mounjaro’s Role in Weight Management

As described in our introductory post, Mounjaro is a dual‑incretin receptor agonist that activates both GLP‑1 and GIP receptors. It reduces appetite, slows stomach emptying and improves insulin sensitivity[1]. Clinical trials have shown weight‑loss reductions of 15 % to 22 %[2], outperforming single‑hormone drugs like semaglutide (Wegovy). Because Mounjaro carries potent metabolic effects and is associated with gastrointestinal side effects[3], it is reserved for people with severe obesity or type 2 diabetes who have not achieved adequate results from lifestyle changes and other pharmacological options.[4]

Why Eligibility Matters

Mounjaro is not a cosmetic weight‑loss medication. UK regulators emphasise that tirzepatide must be used as part of a comprehensive weight‑management programme that includes diet, physical activity and behavioural support[5]. Overuse or inappropriate prescribing could lead to unnecessary side effects and divert resources from those who need it most. This is why eligibility criteria exist-to ensure that people who stand to gain the most benefit and face the greatest health risks are prioritised.

NHS Eligibility Criteria

NICE Technology Appraisal Recommendations

The National Institute for Health and Care Excellence (NICE) issued technology appraisal TA1026 in December 2024, which forms the basis for NHS prescribing. NICE recommends tirzepatide for weight management only when used with a reduced‑calorie diet and increased physical activity and only if an adult has:

·         A body‑mass index (BMI) of at least 35 kg/m² and at least one weight‑related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease)[5].

·         A lower BMI threshold—usually 2.5 kg/m² less-for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African‑Caribbean heritage, recognising that these groups experience obesity‑related complications at lower BMI levels[6].

NICE states that tirzepatide should not be offered to people with a BMI between 30 kg/m² and 35 kg/m² unless they fall within these higher‑risk ethnic categories[7]. Treatment should be reassessed after six months on the maximum tolerated dose; if less than 5 % of initial body weight has been lost, clinicians should evaluate whether to continue[8].

NHS England Implementation (2025–2027)

While NICE provides overarching guidance, NHS England is responsible for rolling out tirzepatide across services. Due to limited availability and the need to build capacity within specialist weight‑management teams, the NHS has adopted a phased approach:

1. Specialist Weight‑Management Services (from 23 March 2025) – Tirzepatide will initially be available only through specialist weight‑management services where multidisciplinary teams provide diet, exercise and psychological support[9]. Patients must have a BMI of at least 40 kg/m² (or 37.5 kg/m² for ethnic‑minority groups) and at least four weight‑related conditions such as type 2 diabetes, hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea[10]. Only those at the highest risk will be offered treatment first.
2. Phased Expansion (2026 onwards) – Over the next three years, eligibility will broaden. The Cheshire and Merseyside integrated care board explains that Cohort 2, beginning June 2026, will include people with BMI 35–39.9 kg/m² and at least four of the five specified comorbidities[11]. Cohort 3, starting April 2027, will include people with BMI ≥ 40 kg/m² and three of these conditions[12]. BMI thresholds for ethnic‑minority groups will continue to be reduced by 2.5 kg/m²[13].
3. Primary‑Care Prescribing – Eventually, GPs may prescribe tirzepatide, but NHS England emphasises that early access through primary care will remain limited to those who meet the strict criteria above until specialist services can scale up[14]. Patients should check their local integrated care board for updates[15].

Type 2 Diabetes Treatment Criteria

Mounjaro can also be prescribed for type 2 diabetes management. Diabetes UK notes that adults over 18 with type 2 diabetes can take Mounjaro when three other medications have failed or cannot be tolerated[16]. For diabetes, BMI requirements may be lower: NICE recommends considering tirzepatide for patients with BMI ≥ 30 kg/m² when insulin is not suitable or when weight loss would improve diabetes control[17]. People with a BMI below 35 kg/m² may still qualify if insulin therapy would affect their job (for example, due to risk of hypoglycaemia) or if weight loss is needed to improve other obesity‑related health issues[18].

Private Prescription Eligibility

Private clinics, such as MedCare Health Clinic & Pharmacy, are not bound by the phased NHS rollout and offer tirzepatide more widely. However, ethical practitioners still follow clinical guidelines to ensure safe prescribing. Typical private criteria include:

·         BMI of at least 30 kg/m² with at least one weight‑related condition, or BMI of 27 kg/m² with risk factors. These thresholds align with the marketing authorisation for tirzepatide, which allows use at BMI ≥ 30 kg/m² or ≥ 27 kg/m² with comorbidities[19].

·         Failure of lifestyle interventions– Patients must demonstrate that diet, exercise and behavioural changes have not led to significant weight loss. Private services typically require a consultation and medical history review similar to NHS assessments. MedCare Health Clinic’s process includes photo verification of identity and weight, as well as a health questionnaire to ensure suitability[20].

·         Medical clearance -Private prescribers screen for contraindications, including pregnancy, breastfeeding, severe gastrointestinal disease, pancreatitis or gallbladder problems, and interactions with existing medications. Women using oral contraception or HRT are counselled about absorption issues and advised to use condoms or transdermal HRT[21].

Private treatment can be a solution for people who do not yet qualify for NHS prescriptions or who want more flexibility. Private packages may include injection training, lifestyle coaching and regular follow‑up consultations. Always choose providers registered with the General Pharmaceutical Council (GPhC) and ensure they offer after‑care support.

Who Should Not Take Mounjaro

Eligibility does not just mean meeting BMI and comorbidity thresholds; it also involves ensuring the medicine is safe for the individual. Mounjaro is not suitable for:

·         Pregnancy and breastfeeding-– Tirzepatide is not recommended during pregnancy or if planning pregnancy, and should be avoided during breastfeeding[23].

·         People under 18 years of age -Clinical trials have focused on adults, so safety and efficacy in children and adolescents are not established. Other interventions should be prioritised for younger people.

·         Individuals with severe gastrointestinal disease -Because tirzepatide slows gastric emptying, it may worsen conditions such as gastroparesis. Those with a history of pancreatitis should also avoid GLP‑1/GIP agonists.

·         Patients with certain endocrine disorders or a history of medullary thyroid carcinoma -While more relevant to some GLP‑1 drugs approved in the US, caution is warranted for anyone with thyroid tumours.

·         People taking medications that could interact -When combined with insulin or sulfonylureas, tirzepatide increases the risk of hypoglycaemia[24]. Your prescriber may adjust doses of existing diabetes medicines to reduce this risk. Because tirzepatide slows gastric emptying, it can also reduce the absorption of oral medications, including contraception and HRT[25].

Ethnic Considerations and Health Inequalities

People from Black African, African‑Caribbean, South Asian, Chinese and Middle Eastern backgrounds are more likely to develop obesity‑related conditions at lower BMI levels. NICE and NHS England have therefore reduced BMI thresholds by 2.5 kg/m² for these groups[6][13]. For example, a South Asian woman with a BMI of 32.5 kg/m² and type 2 diabetes may qualify for tirzepatide, whereas someone of European descent would need a BMI of 35 kg/m² or higher. Recognising these differences helps address health inequalities and ensures equitable access to treatment.

What to Expect During an Assessment

Whether seeking treatment through the NHS or privately, the assessment process typically includes:

1.    Medical history and BMI calculation -Clinicians will record your weight, height and calculate BMI. They will also document any weight‑related comorbidities.

2.    Review of previous weight‑loss attempts -You may be asked about diets, exercise programmes and any pharmacological treatments you have tried. Evidence of lifestyle changes is often required before medication is considered[26].

3.    Screening for contraindications and interactions -This includes pregnancy tests, medication reviews and checks for gastrointestinal or endocrine disorders.

4.    Discussion of expectations and commitments -Mounjaro is not a standalone solution. You must commit to a reduced‑calorie diet and increased physical activity for the medicine to be effective[27]. Clinicians will also discuss potential side effects and the need for regular follow‑ups.

5.    Informed consent -Before prescribing, healthcare professionals must ensure you understand the benefits, risks and alternatives. They may also provide training on how to administer the weekly injection[28].

Alternatives If You’re Not Eligible

If you do not meet the criteria for tirzepatide, other options exist:

·         Lifestyle programmes – The NHS offers weight‑management programmes focused on diet, physical activity and behavioural change[27]. GPs can refer you to local services or digital programmes.

·         Other medications – Drugs such as semaglutide (Wegovy) and liraglutide (Saxenda) may be available through specialist services for people with slightly lower BMI thresholds[29]. Orlistat, a lipase inhibitor, can be prescribed to people with BMI ≥ 30 kg/m² or BMI ≥ 28 kg/m² with weight‑related conditions[30]. Over‑the‑counter versions such as Alli® are available at lower doses but should still be taken under pharmacist supervision. Unlike Mounjaro, orlistat works locally in the gut, blocking fat absorption, and its side effects include oily stools and urgent bowel movements[31].

·         Bariatric surgery – For severe obesity (BMI ≥ 40 kg/m² or BMI ≥ 35 kg/m² with a serious health condition), bariatric surgery may be considered if other interventions fail[32]. Surgery provides the most significant and durable weight loss but carries surgical risks and requires lifelong lifestyle changes.

Conclusion

Mounjaro is a promising addition to the weight‑management arsenal but it is not a universal solution. Strict eligibility criteria ensure that the drug is directed toward those with severe obesity or uncontrolled type 2 diabetes who have not responded to other treatments. On the NHS, access is currently restricted to people with very high BMI and multiple comorbidities, with a phased rollout planned over several years[10][33]. Private clinics may offer more flexible access but still require thorough screening and a commitment to lifestyle changes. Before seeking a prescription, consult witH a medcare Healthclinic qualified healthcare professional to explore all weight‑management options and determine whether Mounjaro is right for you.

Internal Links

·         Understanding Mounjaro: How Tirzepatide Works and Its Benefits -learn about the science and clinical evidence behind Mounjaro.

·         How to Use Mounjaro Safely -guidance on dosing schedules, injection technique and lifestyle support.

·         Mounjaro vs Wegovy vs Orlistat -explore how tirzepatide compares with other weight‑loss medicines.

·         Managing Side Effects and Long‑Term Success with Mounjaro -understand how to recognise and manage side effects and sustain weight loss.

References 

[1] [3] [4] [16] [17] [18] [24] [28] Mounjaro – Uses, How it Works and Side Effects | Diabetes UK

[2] Mounjaro (Tirzepatide) Weight Loss – Preston Prescription

[5] [6] [7] [8] [19] [22] Tirzepatide for managing overweight and obesity

[9] [10] [14] [15] [27] NHS England » Weight management injections

[11] [12] [13] [33] Mounjaro (Tirzepatide) – NHS Cheshire and Merseyside

[20] Weight Management Personalized Plans – Medcare-healthclinic & Pharmacy

[21] [23] [25] [26] [29] [30] [31] [32]  Obesity – Treatment – NHS